ERBB2 and breast cancer: In their study, Ryu et al. reported a DT of 103 ± 43 days for triple‐negative breast cancer and a DT of 162 ± 60 days for HER2+ breast cancer compared to a DT of 241 ± 166 days for ER+breast cancer (p < 0.0001).16